🇺🇸

US SEC Filing Intelligence

· daily

US SEC Filings Daily Market Digest — October 08, 2026

Today's stream of 50 SEC filings for October 8, 2026 is dominated by routine foreign private issuer 6-Ks, monthly regulatory returns, and small-cap SPAC and capital-structure housekeeping, with only a handful of market-moving disclosures. The clearest fundamental signals come from large-cap earnings and operating data: PepsiCo delivered a strong Q3 top line (+5.6% net revenue, +17% EPS) but cut full-year core EPS guidance sharply to +2.5-3.5% on input-cost inflation, while TSMC's September revenue rose 54.6% YoY (nine-month revenue +41.1%) despite a 0.6% sequential dip, and ChipMOS posted Q3 revenue up 36.7% YoY with only +0.2% month-over-month momentum in September. Deal activity is concentrated in Drilling Tools International's ~$81M cash plus 17.4M-share acquisition of Saltire/Foxley, which would lift Eastern Hemisphere exposure from ~18% to ~40% of pro forma revenue. Balance-sheet stress shows up in SolarMax (cash down 72.9% since December while receivables rose 37.2%) and in New ERA's $116M letter-of-credit funding that required cash collateral and warrant issuance. Insider flow is almost entirely small-lot purchases at TSMC, which carry low economic weight but signal internal confidence. Overall the day's read is mixed: strong year-over-year growth at mega-cap and Asian semis versus margin pressure and liquidity strain at smaller, financing-dependent issuers.

31 high priority 19 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — October 08, 2026

All six filings originate from a single issuer, MGM Resorts International (Form 4 insider transaction reports), which places the stream's content squarely within the Consumer Discretionary casino/hotel/entertainment focus and index constituent scope. The filings are routine equity-compensation events: on the same reporting window, five executives and the CEO had restricted stock units (RSUs) vest and convert into common stock at a reference price of $30.00, with a portion of each grant withheld to cover tax obligations. Total withholding values range from roughly $10.1K (SVP & Chief Accounting Officer Meinert Todd) to about $383K (CEO William Hornbuckle), with the CEO's transaction the only one tagged at materiality 6/10 given its size. No open-market purchases or sales were reported; all dispositions were tax-withholding events, and sentiment across all six is neutral. Period-over-period comparisons, forward-looking guidance, capital allocation, financial ratios, and transaction valuation data were not present in these filings, so trend, margin, and guidance synthesis is not possible from this set. The dominant market implication is limited: the filings reflect standard executive compensation mechanics rather than a change in management conviction, though the cluster of same-date vestings across the C-suite is a pattern worth noting for context.

6 high priority 6 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — October 08, 2026

Six S&P 500 healthcare filings from October 8, 2026 point to a corporate-action-heavy session dominated by Medtronic's split-off of MiniMed, with the final exchange ratio of 4.5939 MiniMed shares per Medtronic share set and the offer expiring October 9, 2026. Medtronic's two Rule 425/SC TO-I filings together represent the highest-materiality developments in the set, with the offer covering up to 225,361,295 MiniMed shares (80.1% of MiniMed's outstanding shares) and potential oversubscription of an additional 27,452,053 shares. Capital structure housekeeping was also visible: Centene is fully redeeming its remaining $568.7M 4.25% 2027 Notes on October 23, 2026 at par plus accrued interest, eliminating a near-term maturity without new financing. Shareholder-return signals were routine, with Zoetis declaring a $0.53 quarterly dividend (record October 30, payable December 1, 2026). Insider activity was limited to a single Edwards Lifesciences TAVR executive's 10b5-1 sale of 619 shares at $85.65 (~$53K), retaining roughly 40,034 shares. The filings contain no period-over-period revenue, margin, or guidance data, so trend analysis is constrained; the market implication centers on MiniMed separation mechanics, debt reduction, and dividend continuity rather than operating performance.

4 high priority 2 medium 6 total filings
· daily

US Earnings Financial Results SEC Filings — October 08, 2026

This Financial Results & Earnings digest covers 17 US SEC filings (10-Q and 10-K) for the period, with the first 9 newly published and 8 included for context. The sample splits sharply between large, profitable operators (PepsiCo, Helen of Troy, Richardson Electronics, Oil-Dri) that show revenue growth and margin resilience, and micro-cap or shell-like issuers (Elite Performance, GREENLIT VENTURES, MobbQuest, APPlife, SolarMax) with zero or minimal revenue, negative cash positions and widening deficits. Among mid-caps, homebuilding (KB Home, revenues down 20.0% YoY in Q3) and grocery (Village Super Market, operating margin down to 2.68% from 3.11%) show cyclical or cost-driven pressure, while Tilray and AngioDynamics show revenue growth alongside widening losses or cash burn. Gross margin compression is a recurring theme: Medinotec (61.3% to 48.7% in Q3), APPlife (14.0% to 21.8% improvement but still thin), and Village Super Market (28.57% to 28.17%) highlight cost pressure outpacing pricing. The most material market-moving items are PepsiCo's 46.6% YTD net income jump alongside an $858M currency translation hit, Lottery.com's acquisition-driven balance sheet expansion (goodwill from $7.1M to $59.3M), and KB Home's negative $228.9M operating cash flow over nine months. Overall, the portfolio shows a clear bifurcation between cash-generative franchises and distressed issuers with limited liquidity runway.

17 high priority 17 total filings
· daily

US Executive Compensation Proxy SEC Filings — October 08, 2026

This digest covers nine DEF 14A and DEFM14A filings dated around October 8, 2026, under a stream focused on executive compensation, governance, and shareholder proposals. The filings are dominated by annual meeting notices with proxy proposals (director elections, auditor ratification, say-on-pay, and equity plan changes), so most period-over-period financial comparisons are unavailable in the supplied excerpts. The clearest quantitative compensation trend comes from Leatt Corp, where CEO compensation actually paid rose from $231,762 in 2024 to $623,512 in 2025 (+169%), and average non-PEO NEO pay rose from $433,799 to $746,443 (+72%). AngioDynamics reported FY2026 GAAP revenue growth of 9.5%, with Med Tech up 18.4% and Med Device up only 2.6%, while its equity plan amendment seeks more shares. The most material development is the proposed merger of Cherry Hill Mortgage into TPG Mortgage Investment Trust, though the excerpt lacks deal terms. Governance themes include widespread use of equity plan share increases (Leatt, AngioDynamics, Palomino), reverse-split and blocker-driven ownership opacity (Jaguar Health), and interested-trustee structures (Robinhood Ventures Fund I). Several filings (Siebert, BGC) provided little legible content beyond headers and XBRL tags, which limits assessment.

9 high priority 9 total filings
· daily

US IPO Pipeline SEC S-1 Filings — October 08, 2026

Two SEC filings dated October 8, 2026 fall into the IPO Pipeline / new registrations stream: an S-4 from Boundless Bio, Inc. tied to a pending merger with Seraphа Bio, Inc. (signed June 22, 2026), and an S-4 from Columbus Circle Capital Corp II (now Inflection Point Acquisition Corp. VII) for a proposed SPAC business combination with Elroy Air, Inc., an autonomous aircraft developer. Both filings are neutral in sentiment and rated 7/10 materiality, but the supplied excerpts are largely XBRL tags and header data, so the enriched period-over-period, forward-looking, insider, and capital allocation fields contain no legible dollar amounts, growth rates, or guidance figures. No cross-company margin, growth, or insider patterns can be quantified from this set. The actionable takeaway is that both transactions are registration-stage: deal economics, exchange ratios, pro forma results and shareholder vote timing must be confirmed in the full prospectuses before any position is taken. The most material development is the emergence of a de-SPAC pathway into a capital-intensive hardware sector (autonomous aircraft), which warrants monitoring of redemption levels and funding adequacy.

2 high priority 2 total filings
· daily

US Executive Officer Management Changes SEC — October 08, 2026

This batch of 23 Officer and Director change filings (all dated October 8, 2026 window) is dominated by governance housekeeping, planned succession, and a handful of distressed or governance-stressed situations. Of the 23 filings, roughly 9 carry explicit succession or appointment content with forward-dated effective dates (General Dynamics, MFA Financial, Byline Bancorp, Henry Schein, OGE Energy, Vontier, Gartner, Kirby, Avalon GloboCare), while the rest are routine director resignations or retirements with no-disagreement language. No period-over-period financial metrics were disclosed in any filing, so trend analysis must rely on qualitative signals rather than YoY or QoQ figures. The most market-relevant items are the Lifeward CFO reversal (negative, interim leadership with no permanent CFO), the KonaTel sole-director board (governance concern), and the Avalon GloboCare interim CEO vacancy tied to a drone-defense acquisition pivot. On the positive side, eXp World/AGNT's CEO succession from a founder to an operator with a recent acquisition track record and RB Global's guidance reaffirmation to the high end stand out. Overall the stream signals a cluster of CFO and CLO turnover, which is worth monitoring for execution risk during reorganizations.

23 high priority 23 total filings
· daily

US Corporate Board Director Changes SEC Filings — October 08, 2026

This board-room digest covers 23 SEC 8-K filings dated around October 8, 2026, of which 22 fall within the Officer Change, Director Change, and Board Change scope; one filing (Byline-adjacent scope is retained, but Montrose/Onterris is retained as a director change) — in practice all 23 are governance events, so none are excluded. The dominant theme is leadership succession and planned transitions: General Dynamics' CEO handover (Danny Deep to CEO effective January 1, 2027, with Phebe Novakovic moving to executive chairman after serving since 2013), MFA Financial's CEO succession (Bryan Wulfsohn to CEO July 1, 2027), OGE Energy's COO elevation, and Byline Bancorp's commercial-banking reshuffle. A second cluster is CFO and legal-officer churn: Henry Schein is replacing its CFO after 18 years with incoming CFO Emmanuel Caprais, Gartner's Chief Legal Officer departs October 16, and Lifeward's CFO appointment collapsed before start. Several smaller-cap names show governance stress, most notably KonaTel (board cut to a single director who is also CEO and Chairman) and Avalon GloboCare (interim CEO resigned to pursue a drone-defense acquisition). Period-over-period financial metrics were not disclosed in most of these governance filings, so the analysis relies on qualitative and event-driven signals rather than YoY or QoQ trend data. Market implication: planned, internally driven successions (GD, MFA, OGE, RB Global) are generally low-risk, while unplanned departures at micro-caps and unexplained interim roles warrant closer scrutiny.

23 high priority 23 total filings
· daily

USA Insider Trading Pulse — October 08, 2026

The 'USA Insider Trading Pulse' stream for 2026-10-08 covers 50 SEC Form 4 filings, but the enriched fields provided are limited to insider transaction summaries and holdings: no period-over-period financial comparisons, forward-looking guidance, capital allocation data, financial ratios, or scheduled events were supplied for any filing. The dominant pattern is a cluster of 30 small Taiwan Semiconductor (TSM/2330.TW) insider purchases at a uniform $79.39 price, mostly by VPs and SVPs in lots of roughly 28 to 68 shares (about $2K to $11K each), with the Chairman and CEO's 144-share buy the largest. This looks like coordinated employee share purchase or plan-driven activity rather than a discretionary conviction signal, so its informational value is modest. The most material event is 51Talk Online Education Group's CEO Huang Jack Jiajia buying roughly 1.2 million Class A shares near $11.50 (about $14.1M), which is the strongest open-market conviction signal in the set, while Hello Group, 51Talk, and several bank and REIT filings show routine option exercises, RSU vesting, and tax withholding. Negative signals are limited to a Darden Group President sale (about $448K), a HIVE Digital director sale (about $34K), and a neutral-to-mixed picture from awards and beneficial ownership reports. Overall the stream reads as a mix of routine compensation activity with one standout open-market purchase, and no portfolio-level trend can be confirmed from the data supplied.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — October 08, 2026

This M&A and takeover stream covers nine 8-K filings dated October 7-8, 2026, dominated by SPAC activity: four SPAC-related filings concern IPO closings, extensions, charter amendments or adjournments, while the substantive deal flow is concentrated in three pending or approved business combinations (Calisa/Goodvision AI, Charlton Aria/KQC Quantum, and Digital Asset Acquisition/Titan Strategics uranium). The most material developments are Calisa's shareholder approval of its Goodvision AI business combination with strong For votes (5,903,693 For vs 174,200 Against), the Charlton Aria/KQC Quantum investor webcast on October 8 at 10:30 a.m. ET following a October 6 agreement, and the Digital Asset Acquisition/Titan Strategics deal, which carries a $318 million pro-forma enterprise value but unverified SK-1300 drilling data. Newly launched SPACs (Leader's Advantage with $151.1 million in trust; Southport Acquisition Corp. II with $212.1 million in trust) show continued SPAC IPO issuance, though Leader's Advantage carries a going-concern opinion with no target identified. The stream's financial data is limited: the filings do not provide period-over-period financial comparisons, so trend analysis is confined to deal terms, vote tallies, trust sizing and deadlines. Overall, the stream reflects a SPAC ecosystem in which near-term catalysts are deal closings and extension deadlines rather than fundamental earnings momentum.

9 high priority 9 total filings
· monthly

US Pre-Market SEC Filings Roundup — October 08, 2026

Overnight SEC filings were dominated by insider activity, with a clear cluster of director equity awards at Wave Life Sciences (WLES) and routine tax-related transactions at Coherent Corp. and Streamex Corp. No major 10-K/10-Q earnings releases, M&A, or guidance updates were filed overnight. The most notable signal is the coordinated Wave Life Sciences director compensation package (10 directors each receiving restricted stock and options), suggesting management alignment ahead of upcoming catalysts. Streamex Corp. shows insider selling at low prices, a mildly bearish signal. Overall, the tape is quiet with no material fundamental news.

34 high priority 16 medium 50 total filings
· daily

Biotech Small-Cap Approvals — October 07, 2026

This digest covers 2 FDA approvals from October 2-5, 2026, comprising 0 NMEs, 1 biosimilar, and 1 'Other' (fallback) approval, with no dominant therapeutic area theme. The highest-conviction signal is Aurobindo Pharma Ltd's biosimilar approval for Perampanel (ANDA220492), which is bullish for the entrant as it opens a new revenue stream in the biosimilar market, though bearish for the undisclosed originator. The key risk is the lack of reference product identity for Perampanel, making revenue erosion and market dynamics unquantifiable. Piramal Critical Care's Desflurane approval is a neutral, low-materiality event with no disclosed commercial data.

2 total filings
· daily

Orphan Drug Approvals — October 07, 2026

This period recorded a single, low-conviction Orphan Drug approval, with zero NMEs, zero biosimilars, and zero label expansions, resulting in a muted investment signal. The sole event was a 'FALLBACK' approval for PIRTOBRUTINIB (JAYPIRCA) by LOXO ONCOL, classified as a label expansion but lacking disclosed commercial data on peak sales, exclusivity, or pricing power. The absence of NME or biosimilar activity provides no clear therapeutic area clustering or sponsor pipeline momentum. The highest-conviction signal is a weak bullish (5/10) for PIRTOBRUTINIB, but the lack of detail on market position or near-term catalysts limits actionable insight. Key risk is the opaque nature of this approval—without indication size or competitive context, investors cannot assess revenue impact or IRA exposure for LOXO ONCOL's portfolio.

1 total filings
· daily

New Drug Approvals (Original) — October 07, 2026

During the period of October 7, 2026, the FDA approved two products: one biosimilar (PERAMPANEL by Aurobindo Pharma) and one other/fallback approval (DESFLURANE by Piramal Critical), with no NMEs or label expansions. The approvals are limited to the biosimilar and generic space, with no dominant therapeutic area theme emerging. The highest-conviction signal is the biosimilar approval of PERAMPANEL for Aurobindo, which is bullish for the entrant as it opens a new revenue stream with typical biosimilar discounts, but bearish for the undisclosed originator due to expected revenue erosion. Key risks include the lack of reference product details, which limits assessment of market impact, and the neutral signal for DESFLURANE, which offers limited commercial upside. Investors should watch for launch details and potential interchangeability rulings for PERAMPANEL.

2 total filings
· daily

Federal Construction & Infrastructure Contracts — October 07, 2026

During the period, two civilian construction contracts totaling $273 million were awarded by the Department of Homeland Security (DHS) to Tutor Perini Corporation and Southwest Valley Constructors Co, both for U.S. Customs and Border Protection (CBP) facility construction. The contracts are firm-fixed-price, full-and-open competitive awards, indicating strong competitive positioning for both contractors, but also carrying medium execution risk due to fixed-price structures. The dominant theme is continued DHS investment in border infrastructure, with no defense-related awards. The highest-conviction signal is the sustained federal construction pipeline for large contractors, though the one-time nature of these projects limits recurring revenue visibility. Key watch items include potential cost overruns on fixed-price contracts and the broader impact of continuing resolution uncertainty on future DHS infrastructure spending.

2 total filings
· daily

DHS Homeland Security Contracts — October 07, 2026

Over a single day, the Department of Homeland Security obligated $455.1 million across three contracts, all civilian and all awarded under full-and-open competition with no set-asides, signaling robust, merit-based procurement activity. The dominant theme is DHS/CBP border infrastructure investment, with two large construction awards to Tutor Perini ($144M) and Southwest Valley Constructors ($129M) for new CBP facilities, while MVM, Inc. received the largest single award ($182.1M) for ICE transportation services for unaccompanied minors. The highest-conviction signal is the stable, high-value demand for immigration-related security services, but the time-and-materials pricing structure on MVM’s contract introduces execution risk. Key watch items include potential policy changes affecting ICE’s mission and cost-overrun risks on the fixed-price construction contracts.

3 total filings
· daily

New Federal Contractors — October 07, 2026

This digest covers six new federal contractor awards totaling $907.3 million, all from civilian agencies with zero defense-related contracts, signaling a pronounced shift in procurement activity toward homeland security and justice infrastructure. The Department of Homeland Security dominates the period with three awards—to MVM, Inc. ($182.1M for ICE transportation), Tutor Perini ($144M for a CBP facility), and Southwest Valley Constructors ($129M for another CBP facility)—aggregating $455.1 million, or 50% of total obligation. The highest-conviction signal is V2X Systems LLC’s $166.3 million sole-source award from DOJ, which carries a $1.7 billion potential ceiling if all options are exercised, indicating a deep, non-competitive relationship. Key risks include the fixed-price construction contracts (Tutor Perini, Southwest Valley) exposing margin compression from material cost inflation, and MVM’s politically sensitive immigration mission facing policy-driven disruption. Investors should monitor first outlays on V2X and any re-compete challenges to the sole-source award.

6 total filings
· daily

Significant Contract Modifications ($10M+) — October 07, 2026

This digest covers six significant contract modifications totaling $907.3 million, all from civilian agencies (0% defense-related), with an average signal strength of 4.8/10. The Department of Homeland Security dominates, accounting for $455.1 million (50.2%) across three awards to MVM, Inc., Tutor Perini, and Southwest Valley Constructors for immigration services and border infrastructure. The highest-conviction signal is V2X Systems LLC's $166.3 million sole-source award from DOJ, implying a durable competitive moat, though the time-and-materials pricing and lack of outlays to date introduce execution uncertainty. Key risks include political sensitivity around ICE's immigration mission and fixed-price construction exposure for Tutor Perini and Southwest Valley Constructors. No bullish or bearish signals were identified; all six contracts are rated neutral, reflecting mature, non-catalytic procurement activity with limited near-term investment catalysts.

6 total filings
· daily

Contract Deobligations Alert — October 07, 2026

This digest of six contracts totaling $907.3 million reveals a **purely civilian government spending story** with zero defense exposure, dominated by the Department of Homeland Security (DHS). The highest-conviction signal is a **$1.7 billion potential sole-source award** to **V2X Systems LLC** for DOJ legal support, though current obligations are only $166.3 million with no outlays yet, creating a high-risk/high-reward catalyst. The dominant sector theme is **DHS border and immigration infrastructure**, with three awards totaling **$455.1 million** to MVM, Inc., Tutor Perini, and Southwest Valley Constructors for transportation and facility construction. A key risk is the **time-and-materials pricing** on the two largest contracts (MVM and V2X), which introduces cost variability and execution risk. No bullish or bearish signals were identified across the six neutral-rated contracts, but the concentration in civilian agencies makes this cohort vulnerable to a government shutdown or Continuing Resolution (CR) that disrupts DHS and DOJ funding.

6 total filings
· daily

Contract Option Exercises — October 07, 2026

This digest covers $907.3 million in contract option exercises across six awards, all from civilian agencies (0% defense-related), with an average signal strength of 4.8/10. The dominant theme is Department of Homeland Security (DHS) spending, particularly through ICE and CBP, which accounts for $455.1 million (50.2%) of the total across three awards to MVM, Inc., Tutor Perini, and Southwest Valley Constructors. The highest-conviction signal is V2X Systems LLC’s $166.3 million sole-source award from DOJ, which carries a $1.7 billion potential ceiling if all options are exercised, signaling a strong competitive moat. Key risks include the time-and-materials pricing on the two largest awards (MVM and V2X) exposing contractors to cost variability, and the political sensitivity of ICE’s immigration enforcement mission. No bullish or bearish signals were identified; all six contracts are rated neutral, reflecting balanced risk-reward profiles with no clear catalysts for outperformance or underperformance.

6 total filings